For help on how to get the results you want, see our search tips.
1218 results
Categories
Human Remove Human filter
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Xyrem (updated)
sodium oxybate, Cataplexy, Narcolepsy
Date of authorisation: 13/10/2005, Revision: 31, Authorised, Last updated: 23/04/2021 -
List item
Human medicine European public assessment report (EPAR): Ganfort (updated)
bimatoprost, timolol, Glaucoma, Open-Angle, Ocular Hypertension
Date of authorisation: 19/05/2006, Revision: 20, Authorised, Last updated: 23/04/2021 -
List item
Human medicine European public assessment report (EPAR): Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) (updated)
reassortant influenza virus (live attenuated) of the following strain: A/Vietnam/1203/2004 (H5N1) strain, Influenza, Human
Date of authorisation: 20/05/2016,
, 
, Revision: 7, Authorised, Last updated: 23/04/2021
-
List item
Human medicine European public assessment report (EPAR): Fasenra (updated)
benralizumab, Asthma
Date of authorisation: 08/01/2018,, Revision: 6, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): COVID-19 Vaccine Janssen (updated)
adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S), COVID-19 virus infection
Date of authorisation: 11/03/2021,, , Revision: 1, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Krka d.d. (updated)
emtricitabine, tenofovir disoproxil succinate, HIV Infections
Date of authorisation: 28/04/2017,
, Revision: 8, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Genvoya (updated)
elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide, HIV Infections
Date of authorisation: 19/11/2015, Revision: 22, Authorised, Last updated: 22/04/2021 -
List item
Human medicine European public assessment report (EPAR): Akynzeo (updated)
netupitant, palonosetron hydrochloride, Vomiting, Cancer, Nausea
Date of authorisation: 27/05/2015, Revision: 9, Authorised, Last updated: 22/04/2021 -
List item
Human medicine European public assessment report (EPAR): Kisplyx (updated)
lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016,, 
, Revision: 14, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Zentiva (updated)
emtricitabine, tenofovir disoproxil phosphate, HIV Infections
Date of authorisation: 09/11/2016,, Revision: 5, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Ontruzant (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 15/11/2017,, 
, Revision: 9, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Movymia (updated)
teriparatide, Osteoporosis
Date of authorisation: 11/01/2017,, , Revision: 8, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Isentress (updated)
Raltegravir, HIV Infections
Date of authorisation: 19/12/2007,, Revision: 38, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Cinryze (updated)
C1 inhibitor (human), Angioedemas, Hereditary
Date of authorisation: 15/06/2011,, Revision: 20, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Benepali (updated)
etanercept, Arthritis, Psoriatic, Arthritis, Rheumatoid, Psoriasis
Date of authorisation: 13/01/2016,, Revision: 14, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Synjardy (updated)
empagliflozin, metformin, Diabetes Mellitus, Type 2
Date of authorisation: 27/05/2015,, Revision: 18, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): CoAprovel (updated)
irbesartan, hydrochlorothiazide, Hypertension
Date of authorisation: 14/10/1998, Revision: 42, Authorised, Last updated: 22/04/2021 -
List item
Human medicine European public assessment report (EPAR): Aprovel (updated)
irbesartan, Hypertension
Date of authorisation: 26/08/1997, Revision: 43, Authorised, Last updated: 22/04/2021 -
List item
Human medicine European public assessment report (EPAR): Tasigna (updated)
nilotinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 19/11/2007, Revision: 39, Authorised, Last updated: 22/04/2021 -
List item
Human medicine European public assessment report (EPAR): Ribavirin Teva (updated)
Ribavirin, Hepatitis C, Chronic
Date of authorisation: 31/03/2009,, Revision: 15, Authorised, Last updated: 22/04/2021
-
List item
Human medicine European public assessment report (EPAR): Giotrif (updated)
afatinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 25/09/2013, Revision: 14, Authorised, Last updated: 21/04/2021 -
List item
Human medicine European public assessment report (EPAR): Piqray (updated)
Alpelisib, Breast Neoplasms
Date of authorisation: 27/07/2020,, Revision: 3, Authorised, Last updated: 21/04/2021
-
List item
Human medicine European public assessment report (EPAR): Cabometyx (updated)
cabozantinib (s)-malate, Carcinoma, Renal Cell
Date of authorisation: 09/09/2016,, , Revision: 10, Authorised, Last updated: 21/04/2021
-
List item
Human medicine European public assessment report (EPAR): Reblozyl (updated)
Luspatercept, Anemia, Myelodysplastic Syndromes, beta-Thalassemia
Date of authorisation: 25/06/2020,, 
, Revision: 1, Authorised, Last updated: 21/04/2021
-
List item
Human medicine European public assessment report (EPAR): Opdivo (updated)
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Transitional Cell, Urologic Neoplasms
Date of authorisation: 19/06/2015, Revision: 36, Authorised, Last updated: 21/04/2021